Fig. 6
- ID
- ZDB-FIG-160429-19
- Publication
- Lipscomb et al., 2016 - Dasatinib as a treatment for Duchenne muscular dystrophy
- Other Figures
- (all 6)
- All Figure Page
- Back to All Figure Page
The effect of MG132 treatment on levels of phosphorylated and non-phosphorylated β-dystroglycan in sapje zebrafish larvae. Lysates were made from sapje/ embryos treated from 24 hpf until 96 hpf with 5 μM MG132 or DMSO-only. (A) Western blots probed with antibodies for β-dystroglycan (β-DG) and α-tubulin (α-tub). (B) The density of the blot probed with β-DG was quantified relative to α-tubulin levels in each sample, and normalized to the average control signal. There was a significant increase in the level of β-dystroglycan in larvae treated with MG132, compared with controls (unpaired t-test: t = 4.048, df = 10, P = 0.0023). (C) Western blots probed with antibodies for phosphorylated β-dystroglycan (p-β-DG) and α-tubulin. (D) The density of the blot probed with p-β-DG was quantified relative to α-tubulin levels in each sample, and normalized to the average control signal. There was a significant increase in the levels of β-DG in larvae between different treatment groups (unpaired t-test: t = 11.47, df = 10, P < 0.0001). Graphs represent the mean of six samples from three independent experiments, error bars are SEM. |
Gene: | |
---|---|
Antibodies: | |
Fish: | |
Condition: | |
Anatomical Term: | |
Stage: | Day 4 |
Fish: | |
---|---|
Condition: | |
Observed In: | |
Stage: | Day 4 |